

12

EUROPEAN PATENT APPLICATION

21 Application number: **89810464.1**

51 Int. Cl.4: **A 61 K 35/12**

22 Date of filing: **16.06.89**

30 Priority: **20.06.88 JP 152492/88**

43 Date of publication of application:
27.12.89 Bulletin 89/52

84 Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

71 Applicant: **NIPPON ZOKI PHARMACEUTICAL CO. LTD.**
1-2, 2-chome, Hiranomachi Chuo-ku
Osaka (JP)

72 Inventor: **Konishi, Jin-emon Institute of Bio-Active**
Science
Nippon Zoki Pharmaceutical Co., Ltd. 442-1, Kinashi
Yashiro-cho Katoh-gun Hyogo (JP)

74 Representative: **Kerr, Andrew**
Postfach Finkelerweg 44
CH-4144 Arlesheim (CH)

54 The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases.

57 Physiologically active substances extracted from infected tissue have an NGF-like nerve growth stimulating effect and are used for the manufacture of drugs for the treatment of cerebral and neuronal diseases. These substances are useful as drugs for the treatment of various cerebral and neuronal diseases such as dementia, post-herpetic neuralgia, brain edema and spino-cerebellar degeneration.

Description

The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases

The present invention relates to the use of physiologically active substances extracted from infected tissues for the manufacture of drugs for cerebral and neuronal diseases.

Nerve Growth Factor (NGF) has biological activities stimulating the differentiation and growth of sympathetic and sensory neurons. It has been proposed that there is a relationship between NGF and neuronal diseases affecting peripheral nerves and for this reason NGF has been proposed for the treatment of diseases of this type. In addition, it has recently been found that NGF is produced in the brain and that it has physiological activity there. A correlation has been shown between NGF and the cause of Alzheimer's senile dementia and the use of NGF for the treatment of dementia has been proposed accordingly. Since NGF is a proteinic factor, a number of factors, such as route of administration and pharmaceutical dosage form must, however, be clarified before NGF may be administered to humans. There is therefore a need to develop drugs having a nerve growth stimulating effect similar to that of NGF, but which can easily be administered to humans and which provide greater safety without any undesirable side effects.

It has now been found that physiologically active substances extracted from infected tissues and produced by inoculation with a poxvirus to animal tissues, organs or cultured cells exert an excellent NGF-like action on the nerve system.

It is an object of the present invention to provide physiologically active substances which have been extracted from infected tissues inoculated with a poxvirus, for the manufacture of drugs for the treatment of cerebral and neuronal diseases.

The physiologically active substances of the present invention can be prepared as follows:

- 1) Infected tissues are homogenized with an extraction medium and tissue fragments removed.
- 2) The so-obtained extracted solution is subjected to treatment to remove proteins.
- 3) An adsorbent is added to the deproteinized solution after which the material adsorbed onto the adsorbent is eluted.

The term "infected tissues" as used in this specification is defined as meaning: animal tissues, organs or cultured cells inoculated or infected with a poxvirus.

A poxvirus, for example orthopox virus such as vaccinia virus, cowpox virus, variola virus, infectious ectromelia virus or monkey pox virus; parapoxvirus such as orf virus, paravaccinia virus or bovine papular stomatitis virus; capripoxvirus such as sheeppox virus, goatpox virus or lumpy skin disease virus; avipoxvirus such as fowlpox virus or hare fibroma virus, leporipoxvirus such as rabbit myxoma virus or rabbit fibromas virus, swinepoxvirus, Yaba monkey tumor virus or Tarapox virus, can be used.

The infected tissues may be collected from various kinds of animals or birds, such as rabbit,

sheep, goat, pig, cow, horse, monkey, hamster, guinea pig, rat, mouse or hen. The animal or bird may be selected according to a species of poxvirus and to other conditions. Any type of cultured cell in which the selected poxvirus can multiply may also be selected, such as cultured cells or tumour cells of kidney, skin, lung, testis, liver, muscle, adrenal or thyroid gland, brain, nerve cell or blood cell of rabbit, sheep, goat, pig, cow, horse, monkey, hamster, guinea pig, rat, mouse, hen or embryos thereof. Cultured cells derived from humans, such as Hela cell or decidua of the hatching egg may also be employed.

The infected tissues are collected under aseptic conditions and ground until they are as small as possible. After addition of an extraction medium to the ground material the product is then homogenized. Extraction media that may be used include distilled water, physiological saline, weakly acidic or basic buffers etc. If desired a stabilizer such as glycerin, a disinfectant or preservative such as phenol, or an inorganic salt such as sodium chloride, potassium chloride or magnesium chloride may be added to the medium. Extraction may be facilitated by a procedure designed to disintegrate cell tissues, such as freeze-thaw extraction, sonication or treatment with a detergent or an enzyme which dissolves cell membrane.

The resulting emulsion is filtered or centrifuged to remove tissue fragments. The filtrate or supernatant is deproteinized according to a known method, for example by heating, sonication, treatment with a protein denaturant such as an acid, a base, urea, guanidine, an organic solvent or a detergent, iso-electric point precipitation or salting-out technique. The denatured proteins precipitated in this manner are then removed by filtration using a filter paper made of, for example, cellulose or nitrocellulose, a glass filter, sellaite, Seitz's filter, etc., ultrafiltration, gel filtration, ion-exchange chromatography or centrifugation.

The resulting extract containing the active substances is acidified, preferably to a pH of 3.5 - 5.5 by addition of an acid such as hydrochloric acid, sulfuric acid or hydrobromic acid, and then subjected to adsorption on an adsorbent such as active carbon, kaolin or an ion-exchange resin. The adsorbent may be added to the extracted solution with subsequent stirring, or alternatively the extracted solution may be passed through a column containing the adsorbent.

To elute the material containing the active substances of the present invention a basic solution is added to the adsorbent, the suspension is preferably adjusted to a pH of from 9 to 12 and the mixture is then incubated or stirred at room temperature or heated to a suitable temperature above room temperature. Elution is effected by removing the adsorbent according to a known method, such as filtration or centrifugation. The eluate thus obtained is preferably adjusted to a pH of 6.5 - 8.5 and then

concentrated to dryness under reduced pressure or, alternatively, lyophilized to yield the active substances of the invention.

The physical and chemical properties of the physiologically active substances obtained as set out above are as follows:

1) Appearance:

Pale yellowish brown, hygroscopic powder.

2) Solubility

Soluble in water, methanol and ethanol.

3) Ultraviolet adsorption: λ max = 255 - 275 nm.

4) Ninhydrin reaction: positive.

5) One ml of perchloric acid is added to 2 mg of the substances of the present invention and the mixture heated until the solution becomes colourless. 3 ml of dilute hydrochloric acid, 0.4 g of amidol hydrochloride and 8 g of sodium hydrogen sulfite are dissolved in 100 ml of water. 2 ml of the resulting aqueous solution are then mixed with 1 g of ammonium molybdate and 30 ml of water. 2 ml of the resulting mixture is then added to the above solution which contains the substances of the present invention. The resulting solution is blue in colour.

6) 5 mg of the above solution of the present invention are dissolved in 10 ml of water. 0.2 g of orcin and 0.135 g of Iron(II) ammonium sulfate are dissolved in 5 ml of ethanol, 83 ml of hydrochloric acid are added to the mixture which is then made up to 100 ml through addition of water. 3 ml of the resultant mixture are added to 1 ml of the above solution containing the substances of the invention and heated on a water bath. The solution obtained is green in colour.

7) Silver nitrate reagent is added to the aqueous solution of the substances of the present invention and a precipitate is formed.

8) The resulting precipitate contains a base of nucleic acids.

9) Various protein detection methods carried out in the resulting precipitate yielded negative results.

The following examples, which serve merely as illustration and are not intended in any way to limit the scope of the invention, describe the preparation of the physiologically active substances of the present invention.

Example 1

Vaccinia virus was inoculated into the skin of a healthy adult rabbit. The inflamed skin was cut off under aseptic conditions and well macerated. Aqueous phenol solution was added to the ground material, homogenized and the emulsion filtered by centrifugation. The resulting filtrate was adjusted to a pH of from 4.5 to 5.5 and then heated in a stream of 100°C steam. The proteins precipitated in this procedure were removed by filtration, the filtrate was adjusted to a pH of 8.5 to 10.00 by addition of sodium hydroxide, heated to 100°C and filtered. The filtrate was adjusted to a pH of 4.5 and 1.5% active carbon was added thereto. The suspension was stirred for 1 to 5 hours and then filtered. Water was added to the

resulting active carbon and the suspension was adjusted to a pH of from 9.4 to 10.0 through addition of sodium hydroxide. The extraction procedure was carried out by stirring for 3 - 5 hours at 60°C. The suspension was filtered to remove the active carbon. The filtrate was adjusted to a near neutral pH (ca. pH 7) by addition of hydrochloric acid and concentrated to dryness under reduced pressure to yield the substances of the present invention. The yield of the substances of the present invention was 1.5 - 2.0 g per 1 kg of infected skin tissues.

Example 2

Methanol was added to the active carbon adsorbing the substances of the present invention obtained in the same manner as in Example 1 and stirred for 1 hour. The mixture was filtered and the filtrate concentrated to dryness under reduced pressure to yield the substances of the present invention. The yield was 4.0 - 6.0 g per 1 kg of infected skin tissues.

The following descriptions serve to illustrate pharmaceutical studies of the substances of the present invention.

(1) Toxicity test

In an acute toxicity test, the physiologically active substances of the present invention were administered to male and female mice and rats orally, subcutaneously, intraperitoneally and intravenously. The LD₅₀ of the substances of the invention was more than 5,000 mg/kg for any of the routes of administration, regardless of the species and sex of the animals used.

Subacute toxicity tests revealed no abnormality in any of the organs. Reproduction tests revealed no effects on pregnant animal, foetus, newborn or reproductivity of the offspring (F₁).

(2) Nerve growth stimulating activity

The nerve growth stimulating activity of the physiologically active substances of the present invention was investigated using PC12h cells (a rat pheochromocytoma cell line) which respond to NGF by differentiating into sympathetic neuron-like cells.

PC12h cells were planted in a collagen-coated 24-well microplate in DF medium containing 5% horse serum and 5% precolostrum newborn calf serum. After culturing overnight, the medium was replaced with a serum-free medium (DF medium supplemented with human transferrin, bovine insulin and progesterone) with 100 ug/ml of the substances of the present invention and incubated for 3 days under 90% air and 10% CO₂ gas at 37°C. The rate of the number of cell with neurite processes ($\geq 20\mu\text{m}$) was determined by counting cells at random in 10 fields under a phase contrast microscope.

The substances of the present invention were found to have NGF-like neurotrophic activity in respect of neurite outgrowth and cell surface change.

(3) Clinical study

Pharmaceutical compositions containing as active ingredient the substances of the present invention were administered to patients suffering from post-

herpetic neuralgia, brain edema, dementia and spino-cerebellar degeneration.

I. Post-herpetic neuralgia

8 mg of the substances of the present invention were administered orally twice daily to patients suffering from post-herpetic neuralgia for a period of 4 weeks. More than 63% of patients showed more than slight improvement, moderate to marked improvement being noted in about 50% of patients.

II. Brain edema

10 mg to 36 mg of the substances of the invention were administered daily intravenously or by instillation to patients suffering from brain edema for one to two weeks. Treatment was then continued, depending on the condition of the patient, by administering a daily dosage of 8 mg to 16 mg of the substance of the invention orally for a few weeks.

The efficacy of the treatment was monitored by a time course comparison of edema size using a CT scan and by observing symptoms, using a neurological evaluation rating scale.

Comparing the efficacy of the substances of the present invention with that of steroid hormone therapy, the results on the 10th day of treatment showed that the substances of the invention were significantly superior to those produced by steroid hormones. The substances of the invention produced an improvement in 63% of patients, only 42% of patients showing an improvement after steroid hormone therapy.

III. Dementia

Clinical studies were carried out on patients suffering from cerebral organic disorders, vascular dementia and Alzheimer's dementia. About 10 mg of the substances of the present invention were administered daily to these patients intravenously or by instillation.

Efficacy was evaluated by Hasegawa's simple mental function evaluation scale, scoring degrees of psychopathological conditions such as volition and emotion, scoring degrees of actions in daily life (ADL), clinical tests such as EEG and CT scan and GBS scale (a rating scale for dementia syndromes).

Of the patients treated for 8 weeks with the substances of the present invention, more than about 70% showed improvements in motility, volition, speech disorders, attention, memory, incontinence, emotional disorders and the like.

IV. Spino-cerebellar degeneration

3 mg to 8 mg of the substances of the present invention were administered daily intravenously to 4 members of a family suffering from spino-cerebellar degeneration. 2 patients were in a terminal stage and failed to respond to treatment. Of the 2 remaining cases, where the disease was evolutive, a spectacular improvement was observed in such symptoms as incontinence, motor incoordination, defective vision, nocturnal spasm and ataxic gait. The effect became evident after about 2 months of treatment.

In one evolutive case, treatment was discontinued for 2 weeks. All the pathological symptoms that

reappeared during this period disappeared again when treatment with the substances of the present invention was resumed.

No severe side effects were reported during these clinical trials, only such side effects as sleeplessness, sweating, thirst and gastrointestinal disorders being reported.

It follows from the above-mentioned results that the physiologically active substances of the present invention have an NGF-like nerve growth stimulating effect and can consequently repair injured cerebral and nerve cells or cells having diminished physiological function. It follows that the substances of the invention are useful as drugs for the treatment of vascular dementia caused by cerebral arteriosclerosis, postencephalitis, postapopleptic disorder or post-traumatic syndrome after head injury, Alzheimer's disease including Alzheimer's senile dementia, subcortical dementia such as Huntington's chorea or Parkinson's disease, cerebral diseases such as brain edema and spinocerebellar degeneration, and neuronal diseases such as autonomic imbalance and post-herpetic neuralgia caused by morbidity or injury of sympathetic nerves or sensory nerves.

The substances of the invention have low toxicity and great safety. They are consequently suitable for oral long-term, continuous administration.

The substances of the present invention may be made up into pharmaceutical compositions through combination with appropriate pharmaceutically acceptable carriers or diluents, and may be formulated into preparations in solid, semisolid, liquid or gaseous form such as tablets, capsules, powders, granules, solutions and suppositories in a conventional manner for oral or parenteral administration.

In pharmaceutical dosage forms, the substances of the present invention may be used alone or in appropriate association, as well as in combination with other pharmaceutically active components.

In the case of oral preparations, the substances may be used alone or in combination with appropriate adjuvants in the form of tablets, powders, granules or capsules, e.g. with conventional adjuvants such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as corn starch, potato starch or calcium carboxymethylcellulose; with lubricants such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.

The substances of the present invention may be formulated into preparations for injection by dissolving, suspending or emulsifying in aqueous or non-aqueous solvents, such as distilled water for injection purposes, physiological saline solution, 5-20% glucose aqueous solution, vegetable oil, synthetic aliphatic acid glycerides, esters of higher aliphatic acid or propylene glycol; and if desired, with conventional adjuvants such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives. The substances of the present invention may also be formulated into

lyophilized preparations in vials, which are used as injections by dissolving with the said solvent.

Furthermore, the substances of the invention may be made up into suppositories by mixing with a variety of bases, e.g. emulsifying bases or water-soluble bases, and may also be made up into inhalations or aerosol preparations.

The preferred dose of the substances of the present invention varies with the subject, the form of the drug, the method and period of administration. However, in order to obtain useful effects, it is generally recommended to administer 1 to 100 mg orally, preferably 4 to 40 mg daily.

In the case of parenteral administration, e.g. injections, doses of the substance in the order of one tenth to one third of the above dose are preferable as daily doses.

Pharmaceutical compositions which contain the substances of the present invention as an active ingredient are described below.

Formulation Example 1 (Tablet)

Ingredient	Amount in one tablet (mg)
Substance of the invention	4
Lactose	106
Crystalline cellulose	40
Calcium carboxymethylcellulose	20
Magnesium stearate	10
	Total 180 mg

Formulation Example 2 (Capsule)

Ingredient	Amount in one capsule (mg)
Substance of the invention	10
Lactose	200
Talc	40
	Total 250 mg

Formulation Example 3 (Injection)

Ingredient	Amount in one ampoule (mg)
Substance of the invention	1
Sodium chloride	appropriate amount
Distilled water for injection	appropriate amount
	Total 1 ml

Claims

1. The use of physiologically active substances extracted from infected tissues inoculated with a poxvirus, for the manufacture of drugs for the treatment of cerebral and neuronal diseases.

2. The use as claimed in claim 1, wherein the substances are prepared by extracting from infected tissues inoculated with a poxvirus, deproteinizing the extract, mixing the deproteinized extraction with an adsorbent and eluting the adsorbed material from the adsorbent.

3. The use as claimed in claim 1 or claim 2 wherein the substances possess the following characteristics:

1) appearance: pale yellowish brown, hygroscopic powder.

2) solubility

soluble in water, methanol and ethanol.

3) ultraviolet adsorption: $\lambda_{\max} = 255 - 275 \text{ nm}$.

4) ninhydrin reaction: positive

5) when one ml of perchloric acid is added to 2 mg of substance and the mixture is heated until the solution becomes colourless, then 3 ml of dilute hydrochloric acid, 0.4 g of amidol hydrochloride and 8 g of sodium hydrogen sulfite are dissolved in 100 ml of water, 2 ml of the resulting aqueous solution are mixed with 1 g of ammonium molybdate and 30 ml of water, 2 ml of the resulting mixture is added to the above solution, the resulting solution is blue in colour.

6) when 5 mg of the above solution are dissolved in 10 ml of water. 0.2 g of orcin and 0.135 g of iron(II)ammonium sulfate are dissolved in 5 ml of ethanol, 83 ml of hydrochloric acid are added to the mixture which is then made up to 100 ml through addition of water, 3 ml of the resultant mixture are added to 1 ml of the above solution containing the substances of the invention and heated on a water bath, the resulting solution is green in colour,

7) when silver nitrate reagent is added to an aqueous solution of a substance of the present invention a precipitate is formed,

8) the resulting precipitate contains nucleic acid bases,

9) various protein detection methods carried out in the resulting precipitate yielded negative results.

4. The use as claimed in any one of claims 1 to 3 for the manufacture of drugs for the treatment of dementia.

5. The use as claimed in any one of claims 1 to 3 for the manufacture of drugs for the treatment of cerebral diseases.

6. The use as claimed in claim 5 for the manufacture of drugs for the treatment of brain

edema.

7. The use as claimed in claim 5 for the manufacture of drugs for the treatment of spino-cerebellar degeneration.

8. The use as claimed in any one of claims 1 to 3 for the manufacture of drugs for the treatment of neuronal diseases.

9. The use as claimed in claims 8 for the manufacture of drugs for the treatment of post-herpetic neuralgia.

10. The use as claimed in any one of claims 1 to 9, wherein drugs are formulated into a form suitable for oral administration.

11. The use as claimed in any one of claims 1 to 9, wherein drugs are formulated into a form suitable for parenteral administration.

12. An agent for the treatment of cerebral and neuronal diseases comprising physiologically active substances extracted from infected tissues inoculated with a poxvirus.

13. A pharmaceutical composition for the treatment of cerebral and neuronal diseases comprising physiologically active substances extracted from infected tissues inoculated with a poxvirus.

15

20

25

30

35

40

45

50

55

60

65